Adjuvants: friends in vaccine formulations against infectious diseases
- 21 July 2021
- journal article
- other
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (10) , 3539-3550
Abstract
Infectious diseases represent a major cause of deaths worldwide. No vaccine or effective treatment exists nowadays, especially against intracellular pathogens. The increase in multiple drug and superbug antibiotic resistance strains, excessive medication, or misuse of drugs has prompted the search for other safe and effective alternatives. Consistent with this, adjuvants (Latin word “adjuvare”: “help or aid”) co-administered (Exo) in vaccines have emerged as a promising alternative to initiate and boost an innate, downstream signal that led to adaptative immune response. Nowadays, a promising model of strong immunogens and adjuvants at mucosal sites are the microbial bacterial toxins. Other adjuvants that are also used and might successfully replace aluminum salts in combination with nanotechnology are CpG-ODN, poly IC, type I IFNs, mRNA platforms. Therefore, in the present review, we focused to revisit the old to the new adjuvants compounds, the properties that make them friends in vaccine formulations against infectious diseases.Keywords
Funding Information
- PERFIL PRODEP SEP. MEXICO (2019-2022)
This publication has 100 references indexed in Scilit:
- Designing Vaccines Based on Biology of Human Dendritic Cell SubsetsImmunity, 2010
- Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthraxProceedings of the National Academy of Sciences, 2010
- Pretreatment with Cry1Ac Protoxin Modulates the Immune Response, and Increases the Survival ofPlasmodium-Infected CBA/Ca MiceJournal of Biomedicine and Biotechnology, 2010
- Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvantJournal of Experimental Medicine, 2009
- Intranasal Delivery of Cholera Toxin Induces Th17-Dominated T-Cell Response to Bystander AntigensPLOS ONE, 2009
- Towards an understanding of the adjuvant action of aluminiumNature Reviews Immunology, 2009
- Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cellsJournal of Experimental Medicine, 2008
- Adjuvant-Enhanced Antibody Responses in the Absence of Toll-Like Receptor SignalingScience, 2006
- Toll-like receptor signallingNature Reviews Immunology, 2004
- Molecular identification of a danger signal that alerts the immune system to dying cellsNature, 2003